Rolf Lewensohn Selected Research

Carcinoma (Carcinomatosis)

10/2022	Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome.
1/2016	Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
12/2014	Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.
11/2014	Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.
7/2013	Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
12/2012	Biological effective dose evaluation and assessment of rectal and bladder complications for cervical cancer treated with radiotherapy and surgery.
1/2011	Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer.
8/2004	Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
6/2004	RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide.
11/2003	Heat shock protein 72 does not modulate ionizing radiation-induced apoptosis in U1810 non-small cell lung carcinoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rolf Lewensohn Research Topics

Disease

44	Neoplasms (Cancer) 10/2022 - 01/2002
30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022 - 10/2002
15	Lung Neoplasms (Lung Cancer) 01/2019 - 06/2004
13	Carcinoma (Carcinomatosis) 10/2022 - 01/2002
7	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2020 - 10/2002
6	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2011
5	Neutropenia 04/2022 - 12/2015
5	Pleural Effusion (Pleural Effusions) 12/2021 - 07/2009
5	Adenocarcinoma 11/2021 - 02/2010
5	Breast Neoplasms (Breast Cancer) 01/2019 - 05/2003
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2022 - 06/2008
4	Drug-Related Side Effects and Adverse Reactions 04/2022 - 01/2016
4	Thrombocytopenia (Thrombopenia) 01/2020 - 12/2015
3	Leukopenia 04/2022 - 01/2020
3	Adenocarcinoma of Lung 10/2018 - 07/2009
3	Glioma (Gliomas) 12/2017 - 03/2005
3	Leukemia 06/2009 - 12/2003
2	Melanoma (Melanoma, Malignant) 01/2022 - 08/2021
2	Brain Neoplasms (Brain Tumor) 02/2018 - 12/2007
2	Tics (Tic) 01/2018 - 08/2014
2	Glioblastoma (Glioblastoma Multiforme) 12/2017 - 04/2009
2	Ovarian Neoplasms (Ovarian Cancer) 09/2016 - 12/2015
2	Multiple Myeloma 06/2013 - 08/2004
2	Mitochondrial Diseases (Mitochondrial Disease) 06/2013 - 01/2002
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2010 - 04/2003
2	Prostatic Neoplasms (Prostate Cancer) 10/2008 - 06/2008
1	Disease Progression 05/2022
1	Lung Diseases (Lung Disease) 10/2018
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2018

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2022 - 11/2003
12	Biomarkers (Surrogate Marker)IBA 04/2022 - 06/2008
9	DNA (Deoxyribonucleic Acid)IBA 02/2021 - 04/2003
7	Biological ProductsIBA 01/2019 - 02/2006
6	Gemcitabine FDA Link 04/2022 - 01/2016
6	Pharmaceutical PreparationsIBA 09/2016 - 01/2002
5	Carboplatin (JM8)FDA LinkGeneric 04/2022 - 01/2016
5	Phosphotransferases (Kinase)IBA 01/2019 - 10/2003
5	Melphalan (Alkeran)FDA LinkGeneric 12/2015 - 12/2003
5	CaspasesIBA 06/2013 - 01/2002
4	MicroRNAs (MicroRNA)IBA 05/2022 - 10/2013
4	Tyrosine Kinase InhibitorsIBA 05/2022 - 01/2019
4	PlatinumIBA 04/2020 - 09/2015
4	Small Interfering RNA (siRNA)IBA 01/2018 - 02/2007
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 10/2003
4	melflufenIBA 09/2016 - 06/2013
3	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 02/2021 - 04/2003
3	tyrosine receptor (receptor, tyrosine)IBA 01/2019 - 12/2007
3	Alkylating AgentsIBA 09/2016 - 06/2013
3	Peptide Hydrolases (Proteases)FDA Link 09/2016 - 07/2003
3	ProteomeIBA 02/2010 - 07/2008
3	Etoposide (VP 16)FDA LinkGeneric 08/2004 - 10/2002
2	Gemtuzumab (Mylotarg)FDA Link 06/2022 - 06/2009
2	ErbB Receptors (EGF Receptor)IBA 05/2022 - 01/2019
2	EphrinsIBA 02/2021 - 05/2011
2	Eph Family Receptors (Eph Receptors)IBA 02/2021 - 09/2016
2	Genetic Markers (Genetic Marker)IBA 01/2020 - 01/2020
2	Tumor Biomarkers (Tumor Markers)IBA 01/2019 - 01/2018
2	DNA-Activated Protein KinaseIBA 01/2018 - 08/2004
2	Bleomycin (Blenoxane)FDA LinkGeneric 12/2017 - 08/2007
2	Tamoxifen FDA LinkGeneric 01/2015 - 10/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2014 - 10/2008
2	Insulin-Like PeptidesIBA 08/2014 - 05/2005
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2014 - 04/2009
2	ProdrugsIBA 06/2013 - 09/2007
2	EnzymesIBA 06/2013 - 07/2003
2	DipeptidesIBA 06/2013 - 01/2003
2	Peptides (Polypeptides)IBA 07/2009 - 01/2003
2	Insulin (Novolin)FDA Link 04/2009 - 12/2007
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 04/2009 - 12/2007
2	L-melphalanyl-p-L-fluorophenylalanine ethyl esterIBA 09/2007 - 01/2003
1	Caspase 2IBA 06/2022
1	osimertinibIBA 05/2022
1	AlkanesIBA 04/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 09/2021
1	Erythropoietin FDA Link 02/2021
1	Circulating Tumor DNAIBA 02/2021
1	P-2 (P 2)IBA 01/2020
1	NucleotidesIBA 01/2020
1	Anaplastic Lymphoma KinaseIBA 01/2019
1	CrizotinibIBA 01/2019
1	lorlatinibIBA 01/2019
1	locked nucleic acidIBA 01/2019
1	ChemokinesIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 10/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Vorinostat FDA Link 01/2018
1	EuchromatinIBA 01/2018
1	Lysine (L-Lysine)FDA Link 01/2018
1	Histones (Histone)IBA 01/2018
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2018
1	HeterochromatinIBA 01/2018
1	trichostatin A (A 300)IBA 01/2018

Therapy/Procedure

18	Therapeutics 10/2022 - 01/2002
16	Drug Therapy (Chemotherapy) 12/2021 - 01/2002
12	Radiotherapy 01/2021 - 04/2003
4	Immunotherapy 08/2021 - 01/2018
2	Aftercare (After-Treatment) 09/2021 - 10/2002
2	Prostatectomy (Retropubic Prostatectomy) 10/2008 - 06/2008
1	Precision Medicine 01/2020